Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00070018
Status:
COMPLETED
Last Update Posted:
2022-01-11
First Post:
2003-10-03
Brief Title:
S0313 Cyclophosphamide Doxorubicin Vincristine Prednisone and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkins Lymphoma
Sponsor:
SWOG Cancer Research Network
Organization:
SWOG Cancer Research Network
Study Overview
Official Title:
Evaluation of CHOP Plus Involved Field Radiotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan for Stages I IE and Non-Bulky Stages II and IIE CD20 Positive High-Risk Localized Aggressive Histologies of Non-Hodgkin Lymphoma Phase II
Status:
COMPLETED
Status Verified Date:
2021-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy such as cyclophosphamide doxorubicin vincristine and prednisone use different ways to stop cancer cells from dividing so they stop growing or die Radiation therapy uses high-energy x-rays to damage cancer cells Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells Combining chemotherapy with radiation therapy and monoclonal antibody therapy may kill more cancer cells
PURPOSE This phase II trial is studying how well giving combination chemotherapy together with radiation therapy and monoclonal antibody therapy works in treating patients with stage I or stage II non-Hodgkins lymphoma
PURPOSE This phase II trial is studying how well giving combination chemotherapy together with radiation therapy and monoclonal antibody therapy works in treating patients with stage I or stage II non-Hodgkins lymphoma
Detailed Description:
OBJECTIVES
Determine the 2-year progression-free survival of patients with aggressive high-risk stage I or IE or non-bulky stage II or IIE CD20-positive non-Hodgkins lymphoma treated with cyclophosphamide doxorubicin vincristine and prednisone and radiotherapy followed by rituximab and yttrium Y 90 ibritumomab tiuxetan
Determine the toxicity of this regimen in these patients
OUTLINE This is a multicenter study
Chemotherapy Patients receive CHOP chemotherapy comprising cyclophosphamide IV over 1-2 hours doxorubicin IV and vincristine IV on day 1 and oral prednisone on days 1-5 Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity
Radiotherapy Beginning 3 weeks after the completion of CHOP chemotherapy patients undergo radiotherapy once daily 5 days a week for 4-5 weeks
Monoclonal antibody therapy Beginning 3-6 weeks after the completion of radiotherapy patients receive rituximab IV followed by indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1 Patients then undergo whole body imaging If ibritumomab tiuxetan biodistribution is acceptable patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7 8 OR 9
Patients are followed every 6 months for 2 years and then annually thereafter
PROJECTED ACCRUAL A total of 60 patients will be accrued for this study within 15 months
Determine the 2-year progression-free survival of patients with aggressive high-risk stage I or IE or non-bulky stage II or IIE CD20-positive non-Hodgkins lymphoma treated with cyclophosphamide doxorubicin vincristine and prednisone and radiotherapy followed by rituximab and yttrium Y 90 ibritumomab tiuxetan
Determine the toxicity of this regimen in these patients
OUTLINE This is a multicenter study
Chemotherapy Patients receive CHOP chemotherapy comprising cyclophosphamide IV over 1-2 hours doxorubicin IV and vincristine IV on day 1 and oral prednisone on days 1-5 Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity
Radiotherapy Beginning 3 weeks after the completion of CHOP chemotherapy patients undergo radiotherapy once daily 5 days a week for 4-5 weeks
Monoclonal antibody therapy Beginning 3-6 weeks after the completion of radiotherapy patients receive rituximab IV followed by indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1 Patients then undergo whole body imaging If ibritumomab tiuxetan biodistribution is acceptable patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7 8 OR 9
Patients are followed every 6 months for 2 years and then annually thereafter
PROJECTED ACCRUAL A total of 60 patients will be accrued for this study within 15 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U10CA032102 | NIH | None | None |
| S0313 | OTHER | SWOG | httpsreporternihgovquickSearchU10CA032102 |